Syndax Pharmaceuticals (SNDX) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, gaining 124.3% versus a gain of 2.4%. Over five years, URGN leads with a +116.4% price change compared with -9.1% for SNDX. UroGen Pharma is the larger company by market cap ($1.80 billion vs $1.52 billion), about 1.2 times the size, while Syndax Pharmaceuticals is growing revenue faster (+627.8% vs +21.4%).
UroGen Pharma converts more of its revenue into profit, with a net margin of -139.8% versus -165.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNDX | URGN |
|---|---|---|
| Share price | $16.99 | $36.83 |
| Market cap | $1.52B | $1.80B |
| 1-day change | +0.53% | -0.41% |
| YTD return | -19.56% | +57.26% |
| 1-year return | +2.42% | +124.30% |
| 5-year return | -9.09% | +116.39% |
| Forward P/E | — | 13.18 |
| EPS (TTM) | $-2.52 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $172.35M | $109.79M |
| Revenue growth (YoY) | +627.84% | +21.45% |
| Net income (latest FY) | $-285.42M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | -158.45% | -113.73% |
| Net margin | -165.60% | -139.81% |
| 52-week high | $25.59 | $50.81 |
| 52-week low | $12.99 | $15.86 |
| Distance from 52-week high | -33.61% | -27.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.01% | +62.91% |
| Average volume | 1.55M | 849.01K |
| Shares outstanding | 89.30M | 48.88M |
| Employees | 298 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed SNDX by 121.9 percentage points over the past year.
- UroGen Pharma is more profitable, keeping -139.8 cents of every revenue dollar as net income versus -165.6 cents for Syndax Pharmaceuticals.
- Syndax Pharmaceuticals grew revenue faster in its latest fiscal year (+627.84% vs +21.45%).
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
SNDX vs URGN FAQ
Which is bigger, Syndax Pharmaceuticals or UroGen Pharma?
UroGen Pharma (URGN) is larger, with a market capitalization of $1.80B compared with $1.52B for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, SNDX or URGN?
URGN returned +124.30% over the past 12 months, compared with +2.42% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Syndax Pharmaceuticals and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.